{
  "symbol": "UNH",
  "year": 2022,
  "Period": "Q1",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.1689,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.211
  },
  "top_positive": [
    {
      "sent": "FINANCIAL STATEMENTS UnitedHealth Group Condensed Consolidated Balance Sheets (Unaudited) (in millions, except per share data) September 30, 2022 December 31, 2021 Assets Current assets: Cash and cash equivalents $ 38,845 $ 21,375 Short-term investments 3,682 2,532 Accounts receivable, net 17,047 14,216 Other current receivables, net 13,684 13,866 Assets under management 4,022 4,449 Prepaid expenses and other current assets 5,657 5,320 Total current assets 82,937 61,758 Long-term investments 41,557 43,114 Property, equipment and capitalized software, net 9,469 8,969 Goodwill 83,904 75,795 Other intangible assets, net 10,785 10,044 Other assets 14,412 12,526 Total assets $ 243,064 $ 212,206 Liabilities, redeemable noncontrolling interests and equity Current liabilities: Medical costs payable $ 29,064 $ 24,483 Accounts payable and accrued liabilities 27,232 24,643 Short-term borrowings and current maturities of long-term debt 3,229 3,620 Unearned revenues 12,847 2,571 Other current liabilities 28,563 22,975 Total current liabilities 100,935 78,292 Long-term debt, less current maturities 45,438 42,383 Deferred income taxes 1,659 3,265 Other liabilities 12,111 11,787 Total liabilities 160,143 135,727 Commitments and contingencies (Note 7) Redeemable noncontrolling interests 4,857 1,434 Equity: Preferred stock, $ 0.001 par value - 10 shares authorized; no shares issued or outstanding \u2014 \u2014 Common stock, $ 0.01 par value - 3,000 shares authorized; 935 and 941 issued and outstanding 10 10 Retained earnings 83,722 77,134 Accumulated other comprehensive loss ( 9,086 ) ( 5,384 ) Nonredeemable noncontrolling interests 3,418 3,285 Total equity 78,064 75,045 Total liabilities, redeemable noncontrolling interests and equity $ 243,064 $ 212,206 See Notes to the Condensed Consolidated Financial Statements 1 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Operations (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, (in millions, except per share data) 2022 2021 2022 2021 Revenues: Premiums $ 64,491 $ 56,967 $ 192,457 $ 168,686 Products 9,190 8,703 28,026 25,476 Services 6,700 6,164 19,717 18,181 Investment and other income 513 503 1,175 1,511 Total revenues 80,894 72,337 241,375 213,854 Operating costs: Medical costs 52,635 47,302 157,251 138,752 Operating costs 11,663 10,725 34,773 31,307 Cost of products sold 8,306 7,802 25,389 23,034 Depreciation and amortization 828 796 2,418 2,332 Total operating costs 73,432 66,625 219,831 195,425 Earnings from operations 7,462 5,712 21,544 18,429 Interest expense ( 516 ) ( 422 ) ( 1,416 ) ( 1,229 ) Earnings before income taxes 6,946 5,290 20,128 17,200 Provision for income taxes ( 1,562 ) ( 1,099 ) ( 4,397 ) ( 3,659 ) Net earnings 5,384 4,191 15,731 13,541 Earnings attributable to noncontrolling interests ( 122 ) ( 105 ) ( 372 ) ( 327 ) Net earnings attributable to UnitedHealth Group common shareholders $ 5,262 $ 4,086 $ 15,359 $ 13,214 Earnings per share attributable to UnitedHealth Group common shareholders: Basic $ 5.63 $ 4.33 $ 16.37 $ 14.00 Diluted $ 5.55 $ 4.28 $ 16.15 $ 13.82 Basic weighted-average number of common shares outstanding 935 943 938 944 Dilutive effect of common share equivalents 13 12 13 12 Diluted weighted-average number of common shares outstanding 948 955 951 956 Anti-dilutive shares excluded from the calculation of dilutive effect of common share equivalents 3 1 3 2 See Notes to the Condensed Consolidated Financial Statements 2 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Comprehensive Income (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, (in millions) 2022 2021 2022 2021 Net earnings $ 5,384 $ 4,191 $ 15,731 $ 13,541 Other comprehensive loss: Gross unrealized losses on investment securities during the period ( 1,471 ) ( 192 ) ( 4,825 ) ( 705 ) Income tax effect 340 59 1,109 175 Total unrealized losses, net of tax ( 1,131 ) ( 133 ) ( 3,716 ) ( 530 ) Gross reclassification adjustment for net realized losses (gains) included in net earnings 138 ( 20 ) 134 ( 36 ) Income tax effect ( 32 ) 4 ( 31 ) 8 Total reclassification adjustment, net of tax 106 ( 16 ) 103 ( 28 ) Total foreign currency translation losses ( 331 ) ( 621 ) ( 89 ) ( 484 ) Other comprehensive loss ( 1,356 ) ( 770 ) ( 3,702 ) ( 1,042 ) Comprehensive income 4,028 3,421 12,029 12,499 Comprehensive income attributable to noncontrolling interests ( 122 ) ( 105 ) ( 372 ) ( 327 ) Comprehensive income attributable to UnitedHealth Group common shareholders $ 3,906 $ 3,316 $ 11,657 $ 12,172 See Notes to the Condensed Consolidated Financial Statements 3 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Changes in Equity (Unaudited) Common Stock Additional Paid-In Capital Retained Earnings Accumulated Other Comprehensive (Loss) Income Nonredeemable Noncontrolling Interests Total Equity Three months ended September 30, (in millions) Shares Amount Net Unrealized (Losses) Gains on Investments Foreign Currency Translation Losses Balance at June 30, 2022 935 $ 10 $ \u2014 $ 80,540 $ ( 2,165 ) $ ( 5,565 ) $ 3,385 $ 76,205 Net earnings 5,262 99 5,361 Other comprehensive loss ( 1,025 ) ( 331 ) ( 1,356 ) Issuances of common stock, and related tax effects 2 \u2014 294 294 Share-based compensation 163 163 Common share repurchases ( 2 ) \u2014 ( 462 ) ( 538 ) ( 1,000 ) Cash dividends paid on common shares ($ 1.65 per share) ( 1,542 ) ( 1,542 ) Redeemable noncontrolling interests fair value and other adjustments 5 5 Acquisition and other adjustments of nonredeemable noncontrolling interests 32 32 Distribution to nonredeemable noncontrolling interests ( 98 ) ( 98 ) Balance at September 30, 2022 935 $ 10 $ \u2014 $ 83,722 $ ( 3,190 ) $ ( 5,896 ) $ 3,418 $ 78,064 Balance at June 30, 2021 943 $ 10 $ \u2014 $ 73,090 $ 927 $ ( 5,013 ) $ 3,008 $ 72,022 Net earnings 4,086 86 4,172 Other comprehensive loss ( 149 ) ( 621 ) ( 770 ) Issuances of common stock, and related tax effects 1 \u2014 291 291 Share-based compensation 159 159 Common share repurchases ( 2 ) \u2014 ( 365 ) ( 685 ) ( 1,050 ) Cash dividends paid on common shares ($ 1.45 per share) ( 1,367 ) ( 1,367 ) Redeemable noncontrolling interests fair value and other adjustments ( 85 ) ( 85 ) Acquisition and other adjustments of nonredeemable noncontrolling interests ( 26 ) ( 26 ) Distribution to nonredeemable noncontrolling interests ( 87 ) ( 87 ) Balance at September 30, 2021 942 $ 10 $ \u2014 $ 75,124 $ 778 $ ( 5,634 ) $ 2,981 $ 73,259 See Notes to the Condensed Consolidated Financial Statements 4 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Changes in Equity (Unaudited) Common Stock Additional Paid-In Capital Retained Earnings Accumulated Other Comprehensive Income (Loss) Nonredeemable Noncontrolling Interests Total Equity Nine months ended September 30, (in millions) Shares Amount Net Unrealized Gains (Losses) on Investments Foreign Currency Translation Losses Balance at January 1, 2022 941 $ 10 $ \u2014 $ 77,134 $ 423 $ ( 5,807 ) $ 3,285 $ 75,045 Net earnings 15,359 281 15,640 Other comprehensive loss ( 3,613 ) ( 89 ) ( 3,702 ) Issuances of common stock, and related tax effects 6 \u2014 801 801 Share-based compensation 639 639 Common share repurchases ( 12 ) \u2014 ( 1,679 ) ( 4,321 ) ( 6,000 ) Cash dividends paid on common shares ($ 4.75 per share) ( 4,450 ) ( 4,450 ) Redeemable noncontrolling interests fair value and other adjustments 239 239 Acquisition and other adjustments of nonredeemable noncontrolling interests 135 135 Distribution to nonredeemable noncontrolling interests ( 283 ) ( 283 ) Balance at September 30, 2022 935 $ 10 $ \u2014 $ 83,722 $ ( 3,190 ) $ ( 5,896 ) $ 3,418 $ 78,064 Balance at January 1, 2\n) $ 17,200 16 Table of Contents ITEM\u00a02.",
      "score": 0.9973
    },
    {
      "sent": "Actual results could differ materially from those that management expects, depending on the outcome of certain factors including: risks associated with public health crises, large-scale medical emergencies and pandemics, such as the COVID-19 pandemic; our ability to effectively estimate, price for and manage medical costs; new or changes in existing health care laws or regulations, or their enforcement or application; the DOJ\u2019s legal action relating to the risk adjustment submission matter; our ability to maintain and achieve improvement in quality scores impacting revenue; reductions in revenue or delays to cash flows received under government programs; changes in Medicare, the CMS star ratings program or the application of risk adjustment data validation audits; failure to maintain effective and efficient information systems or if our technology products do not operate as intended; cyberattacks, other privacy/data security incidents, or our failure to comply with related regulations; failure to protect proprietary rights to our databases, software and related products; risks and uncertainties associated with our businesses providing pharmacy care services; competitive pressures, including our ability to develop and deliver innovative products to health care payers and expand access to virtual care; changes in or challenges to our public sector contract awards; failure to develop and maintain satisfactory relationships with health care payers, physicians, hospitals and other service providers; failure to attract, develop, retain, and manage the succession of key employees and executives; the impact of potential changes in tax laws and regulations (including any increase in the U.S.",
      "score": 0.9819
    },
    {
      "sent": "Actual results could differ materially from those that management expects, depending on the outcome of certain factors including: risks associated with public health crises, large-scale medical emergencies and pandemics, such as the COVID-19 pandemic; our ability to effectively estimate, price for and manage medical costs; new or changes in existing health care laws or regulations, or their enforcement or application; the DOJ\u2019s legal action relating to the risk adjustment submission matter; our ability to maintain and achieve improvement in quality scores impacting revenue; reductions in revenue or delays to cash flows received under government programs; changes in Medicare, the CMS star ratings program or the application of risk adjustment data validation audits; failure to maintain effective and efficient information systems or if our technology products do not operate as intended; cyberattacks, other privacy/data security incidents, or our failure to comply with related regulations; failure to protect proprietary rights to our databases, software and related products; risks and uncertainties associated with our businesses providing pharmacy care services; competitive pressures, including our ability to develop and deliver innovative products to health care payers and expand access to virtual care; changes in or challenges to our public sector contract awards; failure to develop and maintain satisfactory relationships with health care payers, physicians, hospitals and other service providers; failure to attract, develop, retain, and manage the succession of key employees and executives; the impact of potential changes in tax laws and regulations (including any increase in the U.S.",
      "score": 0.9819
    }
  ],
  "top_negative": [
    {
      "sent": "By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify.",
      "score": -0.7184
    },
    {
      "sent": "By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify.",
      "score": -0.7184
    },
    {
      "sent": "By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify.",
      "score": -0.7184
    }
  ],
  "forward_snippets": [
    "Readers are cautioned that the statements, estimates, projections or outlook contained in this Management's Discussion and Analysis of Financial Condition and Results of Operations, including discussions regarding financial prospects, economic conditions, trends and uncertainties contained in this Item\u00a02, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA).",
    "We will continue seeking to balance growth and profitability across all these dimensions.",
    "We expect broad-based competition to continue as the industry adapts to individual and employer needs.",
    "2021 Revenues: Premiums $ 64,491 $ 56,967 $ 7,524 13 % $ 192,457 $ 168,686 $ 23,771 14 % Products 9,190 8,703 487 6 28,026 25,476 2,550 10 Services 6,700 6,164 536 9 19,717 18,181 1,536 8 Investment and other income 513 503 10 2 1,175 1,511 (336) (22) Total revenues 80,894 72,337 8,557 12 241,375 213,854 27,521 13 Operating costs: Medical costs 52,635 47,302 5,333 11 157,251 138,752 18,499 13 Operating costs 11,663 10,725 938 9 34,773 31,307 3,466 11 Cost of products sold 8,306 7,802 504 6 25,389 23,034 2,355 10 Depreciation and amortization 828 796 32 4 2,418 2,332 86 4 Total operating costs 73,432 66,625 6,807 10 219,831 195,425 24,406 12 Earnings from operations 7,462 5,712 1,750 31 21,544 18,429 3,115 17 Interest expense (516) (422) (94) 22 (1,416) (1,229) (187) 15 Earnings before income taxes 6,946 5,290 1,656 31 20,128 17,200 2,928 17 Provision for income taxes (1,562) (1,099) (463) 42 (4,397) (3,659) (738) 20 Net earnings 5,384 4,191 1,193 28 15,731 13,541 2,190 16 Earnings attributable to noncontrolling interests (122) (105) (17) 16 (372) (327) (45) 14 Net earnings attributable to UnitedHealth Group common shareholders $ 5,262 $ 4,086 $ 1,176 29 % $ 15,359 $ 13,214 $ 2,145 16 % Diluted earnings per share attributable to UnitedHealth Group common shareholders $ 5.55 $ 4.28 $ 1.27 30 % $ 16.15 $ 13.82 $ 2.33 17 % Medical care ratio (a) 81.6 % 83.0 % (1.4) % 81.7 % 82.3 % (0.6) % Operating cost ratio 14.4 14.8 (0.4) 14.4 14.6 (0.2) Operating margin 9.2 7.9 1.3 8.9 8.6 0.3 Tax rate 22.5 20.8 1.7 21.8 21.3 0.5 Net earnings margin (\noutlook contained in this Management's Discussion and Analysis of Financial Condition and Results of Operations, including discussions regarding financial prospects, economic conditions, trends and uncertainties contained in this Item\u00a02, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA).",
    "We will continue seeking to balance growth and profitability across all these dimensions."
  ]
}